Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials

@article{Citrome2009EffectOZ,
  title={Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials},
  author={Leslie Citrome and Ruoyong Yang and Paul Glue and Onur N. Karayal},
  journal={Schizophrenia Research},
  year={2009},
  volume={111},
  pages={39-45}
}

Risk for Adverse Events and Discontinuation Due To Adverse Events of Ziprasidone Monotherapy Relative to Placebo in the Acute Treatment of Bipolar Depression, Mania, and Schizophrenia

Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups.

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

The findings of this study failed to show that ziprasidone is associated with an elevated risk of nonsuicidal mortality relative to olanzapine in real-world use; the study excludes a relative risk larger than 1.39 with a high probability.

High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms: The ZEBRAS Study

Increasing the ziprasidone dose to 320 mg/d did not produce a sustained elevation in serum concentrations or symptomatic improvement compared with a standard zipraside dose of 160mg/d, and response did not differ between treatment groups.

Using oral ziprasidone effectively: the food effect and dose-response

  • L. Citrome
  • Psychology, Medicine
    Advances in therapy
  • 2009
Oral ziprasidone can be effectively used to control symptoms without the long-term liabilities of metabolic side effects and has important advantages in that it is not associated with clinically significant weight gain or adverse changes in cholesterol, triglycerides, or glycemic control.

Use of ziprasidone in patients with schizophrenia in four European countries

  • J. Montes
  • Medicine, Psychology
    European Psychiatry
  • 2011

Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder

This review aims to provide the latest information on ZPR, an ‘atypical’ agent for the pharmacological therapy of schizophrenia and bipolar disorder, which can be useful for its low tendency to cause metabolic syndrome and hyperprolactinaemia.

Drug safety evaluation of ziprasidone

  • L. Citrome
  • Psychology, Medicine
    Expert opinion on drug safety
  • 2011
Although ziprasidone can prolong the ECG QT interval, this has not resulted in increases in sudden death or cardiac sudden death as noted in a large, simple trial and supported by almost a decade of real-world use in the US.

Evidence review and clinical guidance for the use of ziprasidone in Canada

Ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked comparative data and the available data were either unimpressive or lacking.

References

SHOWING 1-10 OF 25 REFERENCES

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

Results indicate that ziprasidone 120 mg/day is effective in the treatment of the positive, negative and affective symptoms of schizophrenia and schizoaffective disorder with a very low side-effect burden.

A 24-Week Randomized Study of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia or Schizoaffective Disorder in Patients with Prominent Depressive Symptoms

For 24 weeks, olanzapine- treated patients had greater and more sustained participation in treatment, during which time significantly greater improvements were observed in depressive symptoms and GAF scores, along with increases in weight and certain metabolic parameters as compared with ziprasidone-treated patients.

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.

It is suggested that ziprasidone 160mg/day is as effective as haloperidol 15 mg/day in reducing overall psychopathology and positive symptoms of an acute exacerbation of schizophrenia or schizoaffective disorder but has a lower potential to induce extrapyramidal symptoms.

Dose Response and Dose Equivalence of Antipsychotics

Evidence from randomized, placebo-controlled studies of patients with schizophrenia or schizoaffective disorder, which compared 2 or more doses of an antipsychotic to calculate the dose-response curve is reviewed to find 3.3 to 10 mg haloperidol to be the near-maximal ED range.

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

It is demonstrated that ziprasidone was effective in reducing the frequency of relapse and was associated with long-term improvement in negative symptoms and well tolerated in this population of patients with chronic, stable schizophrenia.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.